ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Clinical burden and outcomes of pediatric carbapenem-resistant Klebsiella pneumoniae bloodstream infections in a tertiary care center.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenem-resistant Klebsiella pneumoniae (CRKP) is an emerging threat in pediatric healthcare settings because of limited treatment options and high morbidity and mortality. However, data regarding pediatric CRKP bloodstream infection (BSI) remain limited. This study aimed to evaluate the clinical characteristics and outcomes of CRKP BSI in children.
methodsA retrospective cohort study was conducted among children hospitalized with Klebsiella pneumoniae BSI between 2020 and 2025. Demographic characteristics, healthcare exposures, laboratory findings, antimicrobial therapy, and clinical outcomes were analyzed.
resultsA total of 86 children were included; the median age was 12 months, and 50% were male. Overall, 91.9% had at least one underlying comorbidity, 89.5% had a history of previous hospitalization, 83.3% had prior antibiotic usage, and 25.9% had undergone surgical intervention. During the index hospitalization, 57.0% required intensive care unit admission and 77.6% had at least one invasive device. Fifteen children (17.4%) had CRKP BSI. Prior carbapenem exposure and longer antibiotic use were more frequent in the CRKP group, although the differences were not statistically significant. White blood cell, neutrophil, lymphocyte, and platelet counts were significantly lower in patients with CRKP BSI. Three-month mortality was 40.0% in the CRKP group and 15.9% in the CSKP group, with no statistically significant difference (p = 0.069). Length of hospital stay was also similar between the groups.
conclusionCRKP accounted for 17.4% of K. pneumoniae BSIs in this pediatric cohort. No independent factor associated with carbapenem resistance was identified. The small number of CRKP cases limited the statistical power of the study. Larger multicenter studies are needed to better define factors associated with CRKP and its clinical outcomes in children.
Indexed as
Identifiers
42859370What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.